Your browser doesn't support javascript.
loading
Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema, N G; Tomar, T; van der Zee, A G J; Everts, M; Meersma, G J; Hollema, H; de Jong, S; van Vugt, M A T M; Wisman, G B A.
Afiliação
  • Alkema NG; Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • Tomar T; Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • van der Zee AG; Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • Everts M; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • Meersma GJ; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • Hollema H; Department of Pathology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • de Jong S; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
  • van Vugt MA; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. Electronic address: m.vugt@umcg.nl.
  • Wisman GB; Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. Electronic address: g.b.a.wisman@umcg.nl.
Gynecol Oncol ; 133(3): 591-8, 2014 Jun.
Article em En | MEDLINE | ID: mdl-24657486
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / DNA de Neoplasias / Cisplatino / Cistadenocarcinoma Seroso / Resistencia a Medicamentos Antineoplásicos / Quinase do Ponto de Checagem 2 / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / DNA de Neoplasias / Cisplatino / Cistadenocarcinoma Seroso / Resistencia a Medicamentos Antineoplásicos / Quinase do Ponto de Checagem 2 / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Holanda